The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Synthetic Biology: Protein Design and Engineering Market by Type of Protein Engineering Approach Used (Rational Designing, Directed Evolution and Semi-Rational Designing), Type of Protein (Antibodies, Peptides, Enzymes, Vaccines and Others), Type of Application (Therapeutics and Diagnostics), Type of End User (Pharma / Biotech Firms, CROs and Research / Academic Institutes) and Key Geographies (North America, Europe, APAC, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2022

  • Pages
    242

  • View Count
    1981

Example Insights

Protein-Design-and-Engineering-Market-Context Protein-Design-and-Engineering-Market-List-of-Protein Protein-Design-and-Engineering-Market-Protein-Design-and-Engineering Protein-Design-and-Engineering-Market-Company-Competitiveness-Analysis
Protein-Design-and-Engineering-Market-Technology-Providers Protein-Design-and-Engineering-Market-Engineering-Technologies Protein-Design-and-Engineering-Market-Dot-Plot-Representation Protein-Design-and-Engineering-Market-Partnerships-and-Collaborations
Protein-Design-and-Engineering-Market-Protein-Peptide-Therapeutics Protein-Design-and-Engineering-Market-Patent-Analysis Protein-Design-and-Engineering-Market-Potential-Strategic-Partners Protein-Design-and-Engineering-Market-Distribution-by-Type-of-Protein
Protein-Design-and-Engineering-Market-Services-Market

Overview

Over the past few years, protein-based therapeutics, including peptides, hormones, vaccines, monoclonal antibodies, blood factors and therapeutic enzymes, have gained a lot of attention from clinical researchers engaged in the field of drug development. The success of these therapeutics can be attributed to the various clinical benefits offered by such products, such as high target specificity, low toxicity and favorable safety profiles. It is worth mentioning that, at present, the protein / peptide therapeutic pipeline features over 345 product candidates, which are being evaluated across more than 1,500 clinical trials worldwide. Further, over 55 such therapies have already been marketed to treat multiple therapeutic indications. However, developing a protein based therapeutic is often fraught with several challenges, such as short half-life and poor chemical and physical stability. To overcome the aforementioned challenges as well as enable the development of therapeutic proteins with improved characteristics, researchers have identified various protein design and engineering techniques. Engineering a protein is a complex multistep process which requires high-throughput techniques and screening procedures. Additionally, it is a time and cost intensive process. Therefore, innovators in the pharmaceutical industry are constantly identifying / developing ways to improve the process of protein engineering. 

Amidst other alternatives, outsourcing protein design and engineering process to a specialized service provider, having the required capability, has emerged as a viable option for various protein / peptide therapeutic developers. Presently, over 85 protein design / protein engineering service providers, along with technology providers, are actively supporting the development of novel protein / peptide therapeutics. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in partnership activity related to protein design and engineering. Additionally, over 550 patents related to protein design and engineering techniques have been filed / granted in the past few years, demonstrating the continued innovation being carried out in this domain. Driven by the growing demand for therapeutic proteins for personalized medicine and advancement in protein engineering tools, this market is anticipated to witness steady growth in the coming years.

Scope of the Report

The “Protein Design and Engineering Market by Type of Protein Engineering Approach Used (Rational Designing, Directed Evolution and Semi-Rational Designing), Type of Protein (Antibodies, Peptides, Enzymes, Vaccines and Others), Type of Application (Therapeutics and Diagnostics), Type of End User (Pharma / Biotech Firms, CROs and Research / Academic Institutes) and Key Geographies (North America, Europe, APAC, Latin America, MENA and Rest of the World)): Industry Trends and Global Forecasts, 2021-2035” report features an extensive study of the current market landscape and future potential of the protein design and engineering services and technology providers. The study features an in-depth analysis, highlighting the capabilities of protein design and engineering services and technology providers engaged in this domain. Amongst other elements, the report features: 

  • A detailed review of the overall landscape of companies offering protein design and engineering services to various organizations, including pharma / biotech firms, CROs and research / academic institutes, along with analysis based on various relevant parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters. The chapter also provides details related to protein design and engineering service(s) offered (protein sequencing, protein library generation, protein screening, protein characterization, protein purification, de-novo protein synthesis and in-silico analysis), additional services offered (protein expression, drug discovery, protein-protein interaction analysis, protein identification, bio imaging of proteins, protein extraction and biological pathway identification), type of protein engineering approach used (directed evolution, rational designing and semi- rational designing), type of protein (antibodies, enzymes, peptides, vaccines and others), type of application (therapeutics and diagnostics) and type of protein expression (cell surface and cell free). 
  • A competitiveness analysis of protein design and engineering service providers, segmented into three categories, namely small (1-50 employees), mid-sized (51-500 employees), and large companies (>500 employees). Within the peer group, companies were ranked based on various relevant parameters, such as supplier power (based on the experience) and company competitiveness (based on parameters, such as number of protein design and engineering services offered, type of technique used, type of protein engineering approach used, number of additional services offered, application areas and type of protein expression).
  • Elaborate profiles of key players that are engaged in offering services for protein design and engineering. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), information on services offered, recent developments and an informed future outlook.
  • A detailed assessment of the current market landscape of protein design and engineering technology providers, featuring analysis based on several parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters. In addition, the chapter highlights an in-depth analysis of various protein design and engineering technologies based on type of protein design and engineering service(s) supported (protein sequencing, protein library generation, protein screening, protein characterization, de novo protein synthesis and in-silico analysis), additional services supported (drug discovery, protein-protein interaction analysis and protein expression), type of protein engineering approach used (rational designing, directed evolution and semi-rational designing), type of protein (proteins / peptides, antibodies, enzymes, cytokines and viruses) and type of application (therapeutics and diagnostics).
  • An insightful 2×2 matrix representation of the competitiveness analysis of various protein design and engineering technologies segregated into two peer groups based on the company size of their respective technology provider, namely small (1-50 employees) and mid-sized companies (51-500 employees). Within the peer group, technologies were ranked based on various relevant parameters, such as supplier power (based on the experience of the technology provider) and technology competitiveness (based on  parameters, including number of protein design and engineering services supported, number of additional services supported, type of protein and type of application).
  • Elaborate profiles of key players that are engaged in offering technologies for protein design and engineering. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), information on technology offered, recent developments and an informed future outlook.
  • An analysis of the partnerships that have been inked by stakeholders engaged in this domain, during the period 2017-2021, covering R&D agreements, technology licensing agreements, product development and commercialization agreements, research agreements, service alliances, product development agreements, acquisitions / mergers, technology / software development agreements and other related agreements.
  • An in-depth analysis of over 130 protein / peptide based therapy developers that are likely to partner with protein design and engineering services and technology providers, based on several relevant parameters, such as developer strength (based on company size and its experience), pipeline strength (based on the number of drugs in pipeline and their stage of development and therapeutic area).
  • An in-depth analysis of over 550 patents filed / granted related to protein design and engineering, till 2021. The instances have been analyzed based on various relevant parameters, such as type of patent, application year, publication year, regional applicability, CPC symbols, emerging focus areas, type of applicant, leading patent assignees (in terms of number of patents filed / granted), patent benchmarking and valuation.
  • A detailed analysis of completed, ongoing and planned clinical studies of various protein / peptide based therapies on relevant parameters, such as trial registration year, trial phase, trial recruitment status, type of sponsor, target patient segment, leading industry and non-industry players (in terms of number of registered trials conducted) and key geographical regions.
  • A case study presenting the key characteristics of novel peptide therapeutics, along with information on their applications and advantages, as well as key challenges associated with their development process.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for protein design and engineering market over the coming decade. Additionally, it features market size projections for the protein design and engineering services market, wherein both the current and upcoming opportunity is segmented across [A] type of protein engineering approach used (rational designing, directed evolution and semi - rational designing), [B] type of protein (antibodies, peptides, enzymes, vaccines and others), [C] type of application (therapeutics and diagnostics), [D] type of end user (pharma / biotech firms, CROs and research / academic institutes) and [E] key geographies (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
 
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Roman Badik (Chief Executive Officer, Enantis)
  • Haibin Chen (Vice President, Enzymaster)
  • Naveen Kulkarni (Chief Executive Officer, Quantumzyme)

Key Questions Answered

  • Who are the leading players engaged in providing protein design and engineering services?
  • What is the relative competitiveness of different protein design and engineering service providers?
  • What are the popular types of protein design and engineering technologies available in the market?
  • What types of partnership models are commonly being adopted by stakeholders in this industry? 
  • How is the intellectual property landscape in this field likely to evolve in the foreseen future?
  • Which are the most active clinical trial centers?
  • What are the major market trends and driving factors that are likely to impact the growth of protein design and engineering market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the protein design and engineering market in the short to mid-term and long term.

Chapter 3 provides a general introduction to protein design and engineering, featuring information on various steps involved in the overall process. Further, it provides a detailed discussion on different methods of protein design and engineering. In addition, the chapter includes details related to the various applications and challenges associated with protein design and engineering. The chapter concludes with a discussion on the key growth drivers, as well as upcoming trends in this field.

Chapter 4 includes detailed assessment of the overall landscape of companies offering protein design and engineering services to various organizations, including pharma / biotech firms, CROs and research / academic institutes, along with information on their year of establishment, company size (in terms of employee count) and location of headquarters. The chapter also provides details related to protein design and protein engineering service(s) offered (protein sequencing, protein library generation, protein screening, protein characterization, protein purification, de-novo protein synthesis and in-silico analysis), additional services offered (protein expression, drug discovery, protein-protein interaction analysis, protein identification, bio imaging of proteins, protein extraction and biological pathway identification), type of protein engineering approach used (directed evolution, rational designing and semi- rational designing), type of protein (antibodies, enzymes, peptides, vaccines and others), type of application (therapeutics and diagnostics) and type of protein expression (cell surface and cell free). 

Chapter 5 provides a competitiveness analysis of protein design and engineering service providers, segmented into three categories, namely small (1-50 employees), mid-sized (51-500 employees), and large companies (>500 employees). Within the peer group, companies were ranked based on various relevant parameters, such as supplier power (based on the experience) and their respective capabilities (number of protein design and engineering services offered, type of technique used, protein engineering approaches used, number of additional services offered, application areas and type of protein expression).

Chapter 6 includes detailed profiles of key players offering protein design and engineering services in North America. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), information on protein design and engineering services offered, recent developments and an informed future outlook.

Chapter 7 includes detailed profiles of key players offering protein design and engineering services in Europe. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), information on protein design and engineering services offered, recent developments and an informed future outlook.

Chapter 8 includes detailed profiles of key players offering protein design and engineering services in Asia Pacific. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), information on protein design and engineering services offered, recent developments and an informed future outlook.

Chapter 9 provides a detailed assessment of the current market landscape of protein design and engineering technology providers, featuring information on their year of establishment, company size (in terms of employee count) and location of headquarters. In addition, the chapter highlights an in-depth analysis of various protein design and engineering technologies based on type of protein design and protein engineering service(s) supported (protein sequencing, protein library generation, protein screening, protein characterization, de novo protein synthesis and in-silico analysis), additional services supported (drug discovery, protein-protein interaction analysis and protein expression), type of protein engineering approach used (rational designing, directed evolution and semi-rational designing), type of proteins (proteins / peptides, antibodies, enzymes, cytokines and viruses) and type of application (therapeutics and diagnostics).

Chapter 10 presents an insightful 2×2 representation of the competitiveness analysis of various protein design and engineering technologies segregated into two peer groups based on the company size of their respective technology provider, namely small (1-50 employees) and mid-sized companies (51-500 employees). Within the peer group, technologies were ranked based on various relevant parameters, such as supplier power (based on the experience / expertise of the technology provider) and key technology specifications (number of protein design and protein engineering services supported, number of additional services supported, type of proteins and type of application).

Chapter 11 includes detailed profiles of key players offering protein design and engineering technologies. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), information on protein design and engineering technologies offered, recent developments and an informed future outlook.

Chapter 12 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market, during the period 2017-2021 . Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership (R&D agreements, technology licensing agreements, product development and commercialization agreements, research agreements, service alliances, product development agreements, acquisitions / mergers, technology / software development agreements and other related agreements), and regional distribution of the collaborations.

Chapter 13 present an in-depth analysis of over 90 protein / peptide based therapy developers that are likely to partner with protein design and engineering services and technology providers, based on several relevant parameters, such as developer strength (on the basis of company size and its experience), pipeline strength and maturity (on the basis of number of drugs in pipeline and their stage of development) and therapeutic area.

Chapter 14 provides an in-depth over 550 patents filed / granted related to protein design and engineering, till 2021. The instances have been analyzed based on various relevant parameters, such as type of patent, publication year, regional applicability, CPC symbols, emerging focus areas, type of applicant, leading patent assignees (in terms of number of patents filed / granted), patent benchmarking and valuation.

Chapter 15 provides a detailed analysis of completed, ongoing and planned clinical studies of various protein / peptide based therapies on relevant parameters, such as trial registration year, trial recruitment status, phase of development, target patient segment, type of sponsor, most active players (in terms of number of registered trials conducted) and key geographical regions.

Chapter 16 presents case study presenting the key characteristics of novel peptide therapeutics, along with information on their applications and advantages, as well as key challenges associated with their development process.

Chapter 17 presents an insightful market forecast analysis, highlighting the future potential of protein design and engineering services market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented across important market segments, namely [A] type of protein engineering approach used (rational designing, directed evolution and semi - rational designing), [B] type of protein (antibodies, peptides, enzymes, vaccines and others), [C] type of application (therapeutics and diagnostics), [D] type of end user (pharma / biotech firms, CROs and research / academic institutes) and [E] key geographies (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world). 

Chapter 18 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 19 provides the transcripts of interviews conducted with key stakeholders of this market. In this chapter, we have presented the details of our conversation with Roman Badik (Chief Executive Officer, Enantis), Haibin Chen (Vice President, Enzymaster) and Naveen Kulkarni (Chief Executive Officer, Quantumzyme).

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 21 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Protein Design and Engineering
3.3. Protein Design and Engineering Process
3.3.1. Protein Sequencing
3.3.2. Protein Library Generation
3.3.3. Protein Screening
3.3.4. Protein Expression
3.3.5. Protein Characterization
3.3.6. Protein Quantification
3.3.7. Protein Purification
3.3.8. In-Silico Analysis

3.4. Methods Used for Protein Design and Engineering
3.4.1 Rational Method
3.4.2 Irrational Method / Directed Evolution Method
3.4.3. De-Novo Protein Design Method
3.4.4. Semi-Rational Method / Combinatorial Method

3.5. Applications of Protein Design and Engineering in Pharmaceutical Industry
3.5.1. Disease Diagnosis
3.5.2. Drug Discovery
3.5.3. Development of Protein based Therapeutics
3.5.4. Enzyme Engineering
3.5.5. Antibody Engineering
3.5.6. Virus Engineering

3.6. Challenges Associated with Protein Design and Engineering
3.7. Concluding Remarks

4. MARKET LANDSCAPE: PROTEIN DESIGN AND ENGINEERING SERVICE PROVIDERS
4.1. Chapter Overview
4.2. Protein Design and Engineering Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Protein Design and Engineering Service(s) Offered
4.2.5. Analysis by Additional Services Offered
4.2.6. Analysis by Type of Protein Engineering Approach Used
4.2.7. Analysis by Type of Protein
4.2.8. Analysis by Type of Application
4.2.9. Analysis by Type of Protein Expression

5. PROTEIN DESIGN AND ENGINEERING SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Protein Design and Engineering Services: Company Competitiveness Analysis
5.4.1. Company Competitiveness Analysis: Small Service Providers
5.4.2. Company Competitiveness Analysis: Mid-Sized Service Providers
5.4.3. Company Competitiveness Analysis: Large Service Providers

6. COMPANY PROFILES: PROTEIN DESIGN AND ENGINEERING SERVICE PROVIDERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. ATUM
6.2.1. Company Overview
6.2.2. Protein Design and Engineering Service Offerings
6.2.3. Protein Design and Engineering Technologies
6.2.4. Recent Developments and Future Outlook

6.3. Creative BioMart
6.3.1. Company Overview
6.3.2. Protein Design and Engineering Service Offerings
6.3.3. Recent Developments and Future Outlook

6.4. Creative Biostructure
6.4.1. Company Overview
6.4.2. Protein Design and Engineering Service Offerings
6.4.3. Recent Developments and Future Outlook

6.5. Creative Enzymes
6.5.1. Company Overview
6.5.2. Protein Design and Engineering Service Offerings
6.5.3. Recent Developments and Future Outlook

7. COMPANY PROFILES: PROTEIN DESIGN AND ENGINEERING SERVICE PROVIDERS IN EUROPE
7.1. Chapter Overview
7.1. Absolute Antibody
7.1.1. Company Overview
7.1.2. Protein Design and Engineering Service Offerings
7.1.3. Recent Developments and Future Outlook

7.2. EUCODIS Bioscience
7.2.1. Company Overview
7.2.2. Protein Design and Engineering Service Offerings
7.2.3. Protein Design and Engineering Technologies
7.2.4. Recent Developments and Future Outlook

7.3. Fusion Antibodies
7.3.1. Company Overview
7.3.2. Protein Design and Engineering Service Offerings
7.3.3. Protein Design and Engineering Technologies
7.3.4. Financial Information
7.3.5. Recent Developments and Future Outlook

7.4. Innovagen
7.4.1. Company Overview
7.4.2. Protein Design and Engineering Service Offerings
7.4.3. Recent Developments and Future Outlook

7.5. ZYMVOL
7.5.1. Company Overview
7.5.2. Protein Design and Engineering Service Offerings
7.5.3. Protein Design and Engineering Technologies
7.5.4. Recent Developments and Future Outlook

8. COMPANY PROFILES: PROTEIN DESIGN AND ENGINEERING SERVICE PROVIDERS IN ASIA PACIFIC
8.1. Chapter Overview
8.2. Averring Biotech
8.2.1. Company Overview
8.2.2. Protein Design and Engineering Service Offerings
8.2.3. Recent Developments and Future Outlook

8.3. EnzymeWorks
8.3.1. Company Overview
8.3.2. Protein Design and Engineering Service Offerings
8.3.3. Recent Developments and Future Outlook

8.4. GeNext Genomics
8.4.1. Company Overview
8.4.2. Protein Design and Engineering Service Offerings
8.4.3. Recent Developments and Future Outlook

8.5. Quantumzyme
8.5.1. Company Overview
8.5.2. Protein Design and Engineering Service Offerings
8.5.3. Protein Design and Engineering Technologies
8.5.4. Recent Developments and Future Outlook

9. MARKET LANDSCAPE: PROTEIN DESIGN AND ENGINEERING TECHNOLOGY PROVIDERS
9.1. Chapter Overview
9.2. Protein Design and Engineering Technology Providers: Overall Market Landscape
9.2.1. Analysis by Year of Establishment
9.2.2. Analysis by Company Size
9.2.3. Analysis by Location of Headquarters
9.2.4. Analysis by Protein Design and Engineering Service(s) Supported
9.2.5. Analysis by Additional Services Supported
9.2.6. Analysis by Type of Protein Engineering Approach Used
9.2.7. Analysis by Type of Protein
9.2.8. Analysis by Type of Application

10. PROTEIN DESIGN AND ENGINEERING TECHNOLOGIES: COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Protein Design and Engineering Technologies: Competitiveness Analysis
10.4.1. Technology Competitiveness Analysis: Small Technology Providers
10.4.2. Technology Competitiveness Analysis: Mid-sized Technology Providers

11. COMPANY PROFILES: PROTEIN DESIGN AND ENGINEERING TECHNOLOGY PROVIDERS
11.1. Chapter Overview
11.2. Arzeda
11.2.1. Company Overview
11.2.2. Protein Design and Engineering Technologies
11.2.3. Recent Developments and Future Outlook

11.3. Cyrus Biotechnology
11.3.1. Company Overview
11.3.2. Protein Design and Engineering Technologies
11.3.3. Recent Developments and Future Outlook

11.4. Enzymaster
11.4.1. Company Overview
11.4.2. Protein Design and Engineering Technologies
11.4.3. Recent Developments and Future Outlook

11.5. Innovative Targeting Solutions
11.5.1. Company Overview
11.5.2. Protein Design and Engineering Technologies
11.5.3. Recent Developments and Future Outlook

11.6. Proteus
11.6.1. Company Overview
11.6.2. Protein Design and Engineering Technologies
11.6.3. Recent Developments and Future Outlook

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Protein Design and Engineering Market: Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year and Type of Partnership
12.3.4. Analysis by Focus Area
12.3.5. Most Active Players: Analysis by Number of Partnerships
12.3.6. Geographical Analysis
12.3.6.1. Region-wise Distribution
12.3.6.2. Country-wise Distribution

13. LIKELY PARTNERS ANALYSIS
13.1. Chapter Overview
13.2. Scoring Criteria and Key Assumptions
13.3. Scope and Methodology
13.4. Potential Strategic Partners
13.4.1. Potential Strategic Partners in North America
13.4.1.1. Most Likely Partners in North America
13.4.1.2. Likely Partners in North America
13.4.1.3. Less Likely Partners in North America

13.4.2. Potential Strategic Partners in Europe
13.4.2.1. Most Likely Partners in Europe
13.4.2.2. Likely Partners in Europe
13.4.2.3. Less Likely Partners in Europe

13.4.3. Potential Strategic Partners in Asia Pacific
13.4.3.1. Most Likely Partners in Asia Pacific
13.4.3.2. Likely Partners in Asia Pacific
13.4.3.3. Less Likely Partners in Asia Pacific

14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Protein Design and Engineering Market: Patent Analysis
14.3.1. Analysis by Application Year
14.3.2. Analysis by Publication Year
14.3.3. Analysis by Geography
14.3.4. Analysis by CPC Symbols
14.3.5. Emerging Focus Areas
14.3.6. Analysis by Type of Organization
14.3.7. Leading Players: Analysis by Number of Patents

14.4. Protein Design and Engineering Market: Patent Benchmarking Analysis
14.4.1. Analysis by Patent Characteristics

14.5. Protein Design and Engineering Market: Patent Valuation Analysis
14.6. Leading Patents by Number of Citations

15. CLINICAL TRIAL ANALYSIS
15.1. Chapter overview
15.2. Scope and Methodology
15.3. Protein / Peptide Therapeutics: Clinical Trial Analysis
15.3.1. Analysis by Trial Registration Year
15.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
15.3.3. Analysis by Trial Phase
15.3.4. Analysis by Recruitment Status
15.3.5. Analysis by Type of Sponsor / Collaborator
15.3.6. Analysis by Target Patient Segment
15.3.7. Leading Industry Players: Analysis by Number of Registered Trials
15.3.8. Leading Non-Industry Players: Analysis by Number of Registered Trials
15.3.9. Analysis of Clinical Trials by Geography
15.3.10. Analysis of Enrolled Patient Population by Geography

16. CASE STUDY: NOVEL PEPTIDE THERAPEUTICS
16.1. Chapter Overview
16.2. Overview of Novel Peptide Therapeutics
16.3. Advantages and Applications of Novel Peptide Therapeutics
16.4. Key Challenges Associated with Novel Peptide Therapeutics

17. MARKET FORECAST AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Forecast Methodology and Key Assumptions
17.3. Global Protein Design and Engineering Services Market, 2021-2035
17.4. Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Protein Engineering Approach Used
17.5. Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Protein
17.6. Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Application
17.7. Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of End User
17.8. Protein Design and Engineering Services Market, 2021-2035: Distribution by Region
17.8.1. Protein Design and Engineering Services Market in North America, 2021-2035
17.8.2. Protein Design and Engineering Services Market in Europe, 2021-2035
17.8.3. Protein Design and Engineering Services Market in Asia Pacific, 2021-2035
17.8.4. Protein Design and Engineering Services Market in Latin America, 2021-2035
17.8.5. Protein Design and Engineering Services Market in MENA, 2021-2035
17.8.6. Protein Design and Engineering Services Market in Rest of the World, 2021-2035

18. CONCLUDING REMARKS

19. EXECUTIVE INSIGHTS
19.1. Chapter Overview
19.2. Enantis
19.2.1. Company Snapshot
19.2.2. Interview Transcript: Roman Badik, Chief Executive Officer

19.3. Enzymaster
19.3.1. Company Snapshot
19.3.2. Interview Transcript: Haibin Chen, Vice President

19.4. Quantumzyme
19.4.1. Company Snapshot
19.4.2. Interview Transcript: Naveen Kulkarni, Chief Executive Officer

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape of Protein Design and Engineering Service Providers
Figure 2.2 Executive Summary: Overall Market Landscape of Protein Design and Engineering Technology Providers
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Patent Analysis
Figure 2.5 Executive Summary: Clinical Trial Analysis
Figure 2.6 Executive Summary: Market Forecast
Figure 3.1 Protein Design and Engineering Process
Figure 3.2 Directed Evolution Process
Figure 3.3 Protein Design and Engineering Applications
Figure 4.1 Protein Design and Engineering Service Providers: Distribution by Year of Establishment
Figure 4.2 Protein Design and Engineering Service Providers: Distribution by Company Size
Figure 4.3 Protein Design and Engineering Service Providers: Distribution by Location of Headquarters (Region-wise)
Figure 4.4 Protein Design and Engineering Service Providers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Protein Design and Engineering Service Providers: Distribution by Company Size and Location of Headquarters
Figure 4.6 Protein Design and Engineering Service Providers: Distribution by Type of Protein Design and Engineering Service(s) Offered
Figure 4.7 Protein Design and Engineering Service Providers: Distribution by Additional Services Offered
Figure 4.8 Protein Design and Engineering Service Providers: Distribution by Type of Protein Engineering Approach Used
Figure 4.9 Protein Design and Engineering Service Providers: Distribution by Type of Protein
Figure 4.10 Protein Design and Engineering Service Providers: Distribution by Type of Application
Figure 4.11 Protein Design and Engineering Service Providers: Distribution by Type of Protein Expression
Figure 5.1 Company Competitiveness Analysis: Dot-plot Analysis of Small Service Providers
Figure 5.2 Company Competitiveness Analysis: Small Service Providers
Figure 5.3 Company Competitiveness Analysis: Mid-Sized Service Providers
Figure 5.4 Company Competitiveness Analysis: Large Service Providers
Figure 7.1 Fusion Antibodies: Annual Revenues, 2016-2020 (EUR Million)
Figure 9.1 Protein Design and Engineering Technology Providers: Distribution by Year of Establishment
Figure 9.2 Protein Design and Engineering Technology Providers: Distribution by Company Size
Figure 9.3 Protein Design and Engineering Technology Providers: Distribution by Location of Headquarters (Region-wise)
Figure 9.4 Protein Design and Engineering Technology Providers: Distribution by Location of Headquarters (Country-wise)
Figure 9.5 Protein Design and Engineering Technology Providers: Distribution by Company Size and Location of Headquarters
Figure 9.6 Protein Design and Engineering Technologies: Distribution by Type of Protein Design and Engineering Service(s) Supported
Figure 9.7 Protein Design and Engineering Technologies: Distribution by Additional Service(s) Supported
Figure 9.8 Protein Design and Engineering Technologies: Distribution by Type of Protein Engineering Approach Used
Figure 9.9 Protein Design and Engineering Technologies: Distribution by Type of Protein
Figure 9.10 Protein Design and Engineering Technologies: Distribution by Type of Application
Figure 10.1 Technology Competitiveness Analysis: Small Technology Providers
Figure 10.2 Technology Competitiveness Analysis: Mid-sized Technology Providers
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2021
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 12.4 Partnerships and Collaborations: Distribution by Focus Area
Figure 12.5 Partnerships and Collaborations: Distribution by Number of Partnerships
Figure 12.6 Most Active Players: Distribution by Location of Headquarters (Region-wise)
Figure 12.7 Partnerships and Collaborations: Distribution by Location of Headquarters (Country-wise)
Figure 14.1 Patent Analysis: Distribution by Type of Patent
Figure 14.2 Patent Analysis: Distribution by Application Year
Figure 14.3 Patent Analysis: Cumulative Distribution by Publication Year
Figure 14.4 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Figure 14.5 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Figure 14.6 Patent Analysis: Distribution by CPC Symbols
Figure 14.7 Patent Analysis: Emerging Focus Areas
Figure 14.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Figure 14.9 Leading Industry Players: Distribution by Number of Patents
Figure 14.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 14.11 Leading Patent Assignees: Distribution by Number of Patents
Figure 14.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Figure 14.13 Patent Analysis: Distribution of Patents by Age (2019-2021)
Figure 14.14 Protein Design and Engineering: Patent Valuation
Figure 15.1 Clinical Trial Analysis: Scope and Methodology
Figure 15.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2021
Figure 15.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2010-2021
Figure 15.4 Clinical Trial Analysis: Distribution by Trial Phase and Number of Registered Trials
Figure 15.5 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Figure 15.6 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 15.7 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status, Pre-2010-2021
Figure 15.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 15.9 Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 15.10 Leading Industry Players: Distribution by Number of Registered Trials
Figure 15.11 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 15.12 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 15.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 17.1 Global Protein Design and Engineering Services Market, 2021-2035 (USD Billion)
Figure 17.2 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Protein Engineering Approach Used (USD Billion)
Figure 17.3 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Protein (USD Billion)
Figure 17.4 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Application (USD Billion)
Figure 17.5 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of End User (USD Billion)
Figure 17.6 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Region (USD Billion)
Figure 17.7 Protein Design and Engineering Services Market in North America, 2021-2035 (USD Billion)
Figure 17.8 Protein Design and Engineering Services Market in Europe, 2021-2035 (USD Billion)
Figure 17.9 Protein Design and Engineering Services Market in Asia Pacific, 2021-2035 (USD Billion)
Figure 17.10 Protein Design and Engineering Services Market in Latin America, 2021-2035 (USD Billion)
Figure 17.11 Protein Design and Engineering Services Market in MENA, 2021-2035 (USD Billion)
Figure 17.12 Protein Design and Engineering Services Market in Rest of the World, 2021-2035 (USD Billion)
Figure 18.1 Concluding Remarks: Overall Market Landscape of Protein Design and Engineering Service Providers
Figure 18.2 Concluding Remarks: Overall Market Landscape of Protein Design and Engineering Technology Providers
Figure 18.3 Concluding Remarks: Partnerships and Collaborations
Figure 18.4 Concluding Remarks: Patent Analysis
Figure 18.5 Concluding Remarks: Clinical Trial Analysis
Figure 18.6 Concluding Remarks: Market Forecast

List Of Tables

Table 4.1 List of Protein Design and Engineering Service Providers
Table 4.2 Protein Design and Engineering Service Providers: Information on Type of Protein Design an Engineering Service(s) offered and Additional Service(s) offered
Table 4.3 Protein Design and Engineering Service Providers: Information on Type of Protein Engineering Approach Used, Type of Protein, Type of Application and Type of Protein Expression
Table 6.1 Leading Protein Design and Engineering Service Providers in North America
Table 6.2 ATUM: Company Snapshot
Table 6.3 ATUM: Protein Design and Engineering Service Offerings
Table 6.4 ATUM: Protein Design and Engineering Technologies
Table 6.5 ATUM: Recent Developments and Future Outlook
Table 6.6 Creative BioMart: Company Snapshot
Table 6.7 Creative BioMart: Protein Design and Engineering Service Offerings
Table 6.8 Creative Biostructure: Company Overview
Table 6.9 Creative Biostructure: Protein Design and Engineering Service Offerings
Table 6.10 Creative Enzyme: Company Snapshot
Table 6.11 Creative Enzyme: Protein Design and Engineering Service Offerings
Table 7.1 Leading Protein Design and Engineering Service Providers in Europe
Table 7.2 Absolute Antibody: Company Snapshot
Table 7.3 Absolute Antibody: Protein Design and Engineering Service Offerings
Table 7.5 EUCODIS Bioscience: Company Snapshot
Table 7.6 EUCODIS Bioscience: Protein Design and Engineering Service Offerings
Table 7.7 EUCODIS Bioscience: Protein Design and Engineering Technologies
Table 7.8 Fusion Antibodies: Company Snapshot
Table 7.9 Fusion Antibodies: Protein Design and Engineering Service Offerings
Table 7.10 Fusion Antibodies: Protein Design and Engineering Technologies
Table 7.11 Fusion Antibodies: Recent Developments and Future Outlook
Table 7.12 Innovagen: Company Snapshot
Table 7.13 Innovagen: Protein Design and Engineering Service Offerings
Table 7.14 ZYMVOL: Company Snapshot
Table 7.15 ZYMVOL: Protein Design and Engineering Service Offerings
Table 7.16 ZYMVOL: Protein Design and Engineering Technologies
Table 7.17 ZYMVOL: Recent Developments and Future Outlook
Table 8.1 Leading Protein Design and Engineering Service Providers in Asia Pacific
Table 8.2 Averin Biotech: Company Snapshot
Table 8.3 Averin Biotech: Protein Design and Engineering Service Offerings
Table 8.4 EnzymeWorks: Company Snapshot
Table 8.5 EnzymeWorks: Protein Design and Engineering Service Offerings
Table 8.6 EnzymeWorks: Recent Developments and Future Outlook
Table 8.7 GeNext Genomics: Company Snapshot
Table 8.8 GeNext Genomics: Protein Design and Engineering Service Offerings
Table 8.9 Quantumzyme: Company Snapshot
Table 8.10 Quantumzyme: Protein Design and Engineering Service Offerings
Table 8.11 Quantumzyme: Protein Design and Engineering Technologies
Table 8.12 Quantumzyme: Recent Developments and Future Outlook
Table 9.1 List of Protein Design and Engineering Technology Providers
Table 9.2 Protein Design and Engineering Technologies: Information on Type of Protein Design and Engineering Service(s) Supported and Additional Service(s) Supported
Table 9.3 Protein Design and Engineering Technologies: Information on Type of Protein Engineering Approach Used, Type of Protein, Type of Application and Type of Protein Expression
Table 11.1 Leading Protein Design and Engineering Technology Providers
Table 11.2 Arzeda: Company Snapshot
Table 11.3 Arzeda: Protein Design and Engineering Technologies
Table 11.4 Arzeda: Recent Developments and Future Outlook
Table 11.5 Cyrus Biotechnology: Company Snapshot
Table 11.6 Cyrus Biotechnology: Protein Design and Engineering Technologies
Table 11.7 Cyrus Biotechnology: Recent Developments and Future Outlook
Table 11.8 Enzymaster: Company Snapshot
Table 11.9 Enzymaster: Protein Design and Engineering Technologies
Table 11.10 Enzymaster: Recent Developments and Future Outlook
Table 11.11 Innovative Targeting Solutions: Company Snapshot
Table 11.12 Innovative Targeting Solutions: Protein Design and Engineering Technologies
Table 11.13 Innovative Targeting Solutions: Recent Developments and Future Outlook
Table 11.14 Proteus: Company Snapshot
Table 11.15 Proteus: Protein Design and Engineering Technologies
Table 11.16 Proteus: Recent Developments and Future Outlook
Table 12.1 Protein Design and Engineering Market: List of Partnerships and Collaborations, 2017-2021
Table 13.1 Most Likely Partners based in North America
Table 13.2 Likely Partners based in North America
Table 13.3 Less Likely Partners based in North America
Table 13.4 Most Likely Partners based in Europe
Table 13.5 Likely Partners based in Europe
Table 13.6 Less Likely Partners based in Europe
Table 13.7 Most Likely Partners based in Asia Pacific
Table 13.8 Likely Partners based in Asia Pacific
Table 13.9 Less Likely Partners based in Asia Pacific
Table 14.1 Patent Analysis: Prominent CPC Symbols
Table 14.2 Patent Analysis: Most Popular CPC Symbols
Table 14.3 Patent Analysis: List of Top CPC Symbols
Table 14.4 Patent Analysis: Summary of Benchmarking Analysis
Table 14.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 14.6 Patent Portfolio: List of Leading Patents (in terms of Highest Relative Valuation)
Table 14.7 Patent Portfolio: List of Leading Patents (in terms of Number of Citations)
Table 16.1 Novel Peptide Therapeutics: Development Pipeline
Table 19.1 Enantis: Company Snapshot
Table 19.2 Enzymaster: Company Snapshot
Table 19.3 Quantumzyme: Company Snapshot
Table 20.1 Protein Design and Engineering Service Providers: Distribution by Year of Establishment
Table 20.2 Protein Design and Engineering Service Providers: Distribution by Company Size
Table 20.3 Protein Design and Engineering Service Providers: Distribution by Location of Headquarters (Region-wise)
Table 20.4 Protein Design and Engineering Service Providers: Distribution by Location of Headquarters (Country-wise)
Table 20.5 Protein Design and Engineering Service Providers: Distribution by Company Size and Location of Headquarters
Table 20.6 Protein Design and Engineering Service Providers: Distribution by Type of Protein Design and Engineering Service(s) Offered
Table 20.7 Protein Design and Engineering Service Providers: Distribution by Additional Services Offered
Table 20.8 Protein Design and Engineering Service Providers: Distribution by Type of Protein Engineering Approach Used
Table 20.9 Protein Design and Engineering Service Providers: Distribution by Type of Protein
Table 20.10 Protein Design and Engineering Service Providers: Distribution by Type of Application
Table 20.11 Protein Design and Engineering Service Providers: Distribution by Type of Protein Expression
Table 20.12 Fusion Antibodies: Annual Revenues, 2016-2020 (EUR Million)
Table 20.13 Protein Design and Engineering Technology Providers: Distribution by Company Size
Table 20.14 Protein Design and Engineering Technology Providers: Distribution by Location of Headquarters (Region-wise)
Table 20.15 Protein Design and Engineering Technology Providers: Distribution by Location of Headquarters (Country-wise)
Table 20.16 Protein Design and Engineering Technology Providers: Distribution by Company Size and Location of Headquarters
Table 20.17 Protein Design and Engineering Technologies: Distribution by Type of Protein Design and Engineering Service(s) Supported
Table 20.18 Protein Design and Engineering Technologies: Distribution by Additional Services Supported
Table 20.19 Protein Design and Engineering Technologies: Distribution by Type of Protein Engineering Approach Used
Table 20.20 Protein Design and Engineering Technologies: Distribution by Type of Protein
Table 20.21 Protein Design and Engineering Technologies: Distribution by Type of Application
Table 20.22 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2021
Table 20.23 Partnerships and Collaborations: Distribution by Type of Partnership
Table 20.24 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 20.25 Partnerships and Collaborations: Distribution by Focus Area
Table 20.26 Partnerships and Collaborations: Distribution by Number of Partnerships
Table 20.27 Most Active Players: Distribution by Location of Headquarters (Region-wise)
Table 20.28 Partnerships and Collaborations: Distribution by Location of Headquarters (Country-wise)
Table 20.29 Patent Analysis: Distribution by Type of Patent
Table 20.30 Patent Analysis: Distribution by Application Year
Table 20.31 Patent Analysis: Cumulative Distribution by Publication Year
Table 20.32 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Table 20.33 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Table 20.34 Patent Analysis: Distribution by CPC Symbols
Table 20.35 Patent Analysis: Emerging Focus Areas
Table 20.36 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Table 20.37 Leading Industry Players: Distribution by Number of Patents
Table 20.38 Leading Non-Industry Players: Distribution by Number of Patents
Table 20.39 Leading Patent Assignees: Distribution by Number of Patents
Table 20.40 Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Symbols)
Table 20.41 Patent Analysis: Distribution of Patents by Age (2019-2021)
Table 20.42 Protein Design and Engineering: Patent Valuation
Table 20.43 Clinical Trial Analysis: Scope and Methodology
Table 20.44 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2021
Table 20.45 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2010-2021
Table 20.46 Clinical Trial Analysis: Distribution by Trial Phase and Number of Registered Trials
Table 20.47 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Table 20.48 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 20.49 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status, Pre-2010-2021
Table 20.50 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 20.51 Clinical Trial Analysis: Distribution by Target Patient Segment
Table 20.52 Leading Industry Players: Distribution by Number of Registered Trials
Table 20.53 Leading Non-Industry Players: Distribution by Number of Registered Trials
Table 20.54 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 20.55 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 20.56 Global Protein Design and Engineering Services Market, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 20.57 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Protein Engineering Approach Used (USD Billion)
Table 20.58 Protein Design and Engineering Services Market, 202 and 2035: Distribution by Type of Protein (USD Billion)
Table 20.59 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Application (USD Billion)
Table 20.60 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of End User (USD Billion)
Table 20.61 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Region (USD Billion)
Table 20.62 Protein Design and Engineering Services Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 20.63 Protein Design and Engineering Services Market in Europe, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 20.64 Protein Design and Engineering Services Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 20.65 Protein Design and Engineering Services Market in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 20.66 Protein Design and Engineering Services Market in MENA, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 20.67 Protein Design and Engineering Services Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1.       13therapeutics
  2.       9 Meters Biopharma
  3.       Ablynx
  4.       Absolute Antibody
  5.       Abzena
  6.       Accelero Biostructures 
  7.       Advanced Accelerator Applications
  8.       AffyPro
  9.       Aileron Therapeutics
  10.       Akashi Therapeutics
  11.       Allozymes
  12.       Allysta Pharmaceuticals
  13.       Altimmune
  14.       Ambrx
  15.       Amgen
  16.       Aminoverse
  17.       Amolyt Pharma
  18.       Ampio Pharmaceuticals
  19.       Amyndas Pharmaceuticals
  20.       Anji Pharmaceuticals
  21.       Apellis Pharmaceuticals
  22.       Apeptico
  23.       APIM Therapeutics
  24.       Apitope
  25.       Aquestive Therapeutics
  26.       Arch Biopartners
  27.       Arzeda
  28.       AsclepiX Therapeutics
  29.       Astellas Pharma
  30.       AstraZeneca
  31.       Atox Bio
  32.       Atreca
  33.       ATUM
  34.       August Bioservices
  35.       Aurinia Pharmaceuticals
  36.       Averin Biotech
  37.       Avilex Pharma
  38.       Bayer
  39.       Bicycle Therapeutics
  40.       BioLineRx
  41.       Biolingus
  42.       Biologics International
  43.       Biomarck Pharmaceuticals
  44.       BioMarin Pharmaceutical
  45.       BioMetis Technology
  46.       BioTickle
  47.       Boehringer Ingelheim
  48.       Boston Therapeutics
  49.       Bristol Myers Squibb
  50.       Broad Institute of MIT and Harvard
  51.       California Institute of Technology
  52.       CanBas
  53.       Cancer Research UK
  54.       candidum
  55.       Cara Therapeutics
  56.       Carmot Therapeutics
  57.       Cellivery Therapeutics
  58.       Cend Therapeutics
  59.       ChemPartner
  60.       Chiasma Pharma
  61.       China Agricultural University
  62.       Chondropeptix
  63.       ChromoTek
  64.       Chrysalis BioTherapeutics
  65.       Clinuvel Pharmaceuticals
  66.       Codex DNA
  67.       Codexis
  68.       CohBar
  69.       Columbia University
  70.       Constant Therapeutics
  71.       Creative Biolabs
  72.       Creative BioMart
  73.       Creative Biostructure
  74.       Creative Enzymes
  75.       CureDM
  76.       Curonz
  77.       Cyrus Biotechnology
  78.       Cytovation
  79.       Cytovia Therapeutics
  80.       Dana-Farber Cancer Institute
  81.       Dezyme
  82.       Diabetology
  83.       Diapin Therapeutics
  84.       DNASTAR
  85.       Early Drug Development Group (E2DG)
  86.       Eli Lilly
  87.       Emory University
  88.       Enantis 
  89.       Entera Bio
  90.       Enteris BioPharma
  91.       Enzymaster
  92.       EnzymeWorks
  93.       Esperance Pharmaceuticals
  94.       EUCODIS Bioscience 
  95.       EUPROTEIN 
  96.       Eurofins
  97.       EvoEnzyme
  98.       Evozyne
  99.       exonbio 
  100. F4 Pharma
  101. Factor Bioscience
  102. Ferring Pharmaceuticals
  103. FinsnoBio
  104. Frontier Korea
  105. Fujitsu 
  106. FirstString Research
  107. Follicum
  108. Fornia BioSolutions
  109. Frontier Biotechnologies
  110. Fusion Antibodies
  111. Genentech
  112. Genervon Biopharmaceuticals
  113. GeNext Genomics
  114. Genomica
  115. GenScript
  116. Genus Oncology
  117. Gila Therapeutics
  118. Gilead Sciences
  119. GlaxoSmithKline
  120. GlioCure
  121. Harvard University 
  122. HELIOPOLIS BIOTECH
  123. HighTide Therapeutics
  124. iBio
  125. ILC Therapeutics
  126. Imcyse
  127. ImmuPharma
  128. Innovagen AB
  129. Innovative Targeting Solutions
  130. Inotrem
  131. Inscripta
  132. Integral Molecular
  133. InterK Peptide Therapeutics
  134. Issar Pharmaceuticals
  135. iXpressGenes
  136. Janssen Biotech
  137. Kalos Therapeutics
  138. Kerafast
  139. La Jolla Pharmaceutical
  140. LabGenius 
  141. Laboratory of Computational Biology 
  142. LakePharma (acquired by Curia)
  143. Lassogen
  144. Lead Discovery Siena
  145. Leland Stanford Junior University
  146. Longevity Biotech
  147. LifeSpan BioSciences (LSBio)
  148. Macromoltek
  149. Massachusetts General Hospital
  150. Massachusetts Institute of Technology
  151. Mayo Clinic
  152. MD Anderson Cancer Center
  153. MedImmune
  154. MElkin Pharmaceuticals
  155. Memorial Sloan Kettering Cancer Center
  156. Merck
  157. MeSCue-Janusys
  158. Mid-Atlantic BioTherapeutics (MABT)
  159. Millennium Pharmaceuticals
  160. Molecular Loop
  161. Molecular Partners
  162. Mologic
  163. Molsoft
  164. Nanomerics
  165. National Cancer Institute (NCI)
  166. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  167. Nestlé Health Science
  168. Neurozon
  169. Next Interactions
  170. NextPharma
  171. NoNO
  172. Nostrum Biodiscovery
  173. NovaCell Technology
  174. Novartis
  175. Novo Nordisk
  176. NVIDIA
  177. NYU Langone Health
  178. Oak BioSciences
  179. Olympic Protein Technologies (OPT) 
  180. ONL Therapeutics
  181. OpenEye Scientific
  182. OPKO Health
  183. Oramed Pharmaceuticals
  184. OriMAbs
  185. Ovoca Bio
  186. Oxalo Therapeutics
  187. Oxurion
  188. Palatin Technologies
  189. PEACCEL 
  190. PEP-Therapy
  191. PeptiDream
  192. Peptilogics
  193. Peptone 
  194. Peptron
  195. PharmaMar
  196. Pieris Pharmaceuticals
  197. PIN Pharma
  198. Plabeltech
  199. Polyclone Bioservices
  200. Polyphor
  201. Porton Pharma Solutions
  202. Priavoid
  203. ProLynx
  204. ProMab Biotechnologies
  205. ProMore Pharma
  206. ProNeurogen
  207. Protagonist Therapeutics
  208. Protein Alternatives SL (PROALT)
  209. Protein Design
  210. ProteinQure
  211. Proteus by Seqens
  212. Pulmotect
  213. Quantum Hi-Tech (China) Biological
  214. Quantumzyme
  215. Queen’s University Belfast
  216. Radius Health
  217. Rani Therapeutics
  218. Ranomics
  219. RD-BIOTECH
  220. Regeneron Pharmaceuticals
  221. RegeneRx Biopharmaceuticals
  222. ReGenTree
  223. Revolve Biotechnologies
  224. Rhythm Pharmaceuticals
  225. Roche
  226. Safic-Alcan
  227. Salix Pharmaceuticals
  228. Sanofi
  229. Santhera Pharmaceuticals
  230. Sapience Therapeutics
  231. Scotia Biologics
  232. Scotia Biologics
  233. Seachaid Pharmaceuticals
  234. Selecta Biosciences
  235. Sentebiolab
  236. Serpin Pharma
  237. SeSaM-Biotech
  238. Soligenix
  239. Soricimed Biopharma
  240. Stealth BioTherapeutics
  241. Structure Based Design (SBD)
  242. Sutro Biopharma
  243. Swedish Orphan Biovitrum (SOBI)
  244. Synbio Technologies
  245. Synbuild
  246. SYNG Pharmaceuticals
  247. Synthorx (acquired by Sanofi)
  248. Takeda Pharmaceuticals
  249. Tarsa Therapeutics
  250. TC BioPharm
  251. TCR2 Therapeutics
  252. TearSolutions
  253. Technical University of Denmark
  254. TeselaGen Biotechnology
  255. The University of Texas
  256. TheraSource
  257. Thermo Fisher Scientific
  258. Topas Therapeutics
  259. Twist Bioscience
  260. TwoToBiotech
  261. University of California, San Francisco (UCSF)
  262. UCB Pharma
  263. UCLA Technology Development Group
  264. University of California
  265. University of Chicago
  266. University of Toronto
  267. University of Washington
  268. Vault Pharma
  269. Vaxeal
  270. Verne Global
  271. Viatem
  272. Vir Biotechnology
  273. Watchmaker Genomics
  274. Xen Biofluidx
  275. Xencor
  276. Xigen
  277. XPose Therapeutics
  278. YUMAB
  279. Zealand Pharma
  280. Zucara Therapeutics
  281. Zummit Infolabs
  282. Zymeworks
  283. Zymvol Biomodeling

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com